Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma

被引:19
作者
Osoegawa, Atsushi [1 ,2 ]
Kometani, Takuro [1 ]
Fukuyama, Seiichi [1 ]
Hirai, Fumihiko [1 ]
Seto, Takashi [1 ]
Sugio, Kenji [1 ,2 ]
Ichinose, Yukito [1 ]
机构
[1] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan
[2] Oita Univ, Dept Thorac & Breast Surg, Fac Med, 1-1 Idaigaoka, Yufu, Oita 8795593, Japan
关键词
pulmonary metastasis; colorectal carcinoma; carcinoembryonic antigen; 1ST-LINE TREATMENT; SURGICAL RESECTION; LUNG METASTASES; PHASE-III; CANCER; LEUCOVORIN; FLUOROURACIL; OXALIPLATIN; IRINOTECAN; BEVACIZUMAB;
D O I
10.5761/atcs.oa.14-00345
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: As chemotherapy has improved, the survival of patients with metastatic colorectal carcinoma has reached up to 2.5 years. Many of these patients experience pulmonary metastases; however, the prognosis after pulmonary metastasectomy is not satisfying. In this study, we analyzed the prognostic factors for survival in patients who underwent pulmonary metastasectomy. Methods: Eighty-seven patients with colorectal carcinoma received pulmonary metastasectomy. The pathological status of the primary tumor, outcome of the pulmonary metastasectomy, disease-free interval, perioperative carcinoembryonic antigen (CEA) level and history of liver metastases were assessed. Results: The five-year survival was 42.5% after pulmonary metastasectomy. A univariate analyses revealed that the CEA level (p = 0.043) and the number of pulmonary metastases (p = 0.047) were prognostic factors for survival. The CEA level was an independent prognostic factor in a multivariate analysis (relative risk = 2.01, p = 0.037). Among cases with elevated preoperative CEA levels, those whose CEA level normalized after metastasectomy had a better prognosis compared with those whose CEA level decreased but was still high, or whose level increased after metastasectomy (median survival time of 41.8 months compared with 28.1 or 15.7 months, respectively p = 0.021). Conclusion: The CEA level can be a predictive marker for the prognosis in patients with pulmonary metastases from colorectal carcinoma.
引用
收藏
页码:6 / 11
页数:6
相关论文
共 36 条
[1]   CLINICAL PERSPECTIVE OF HUMAN COLORECTAL-CANCER METASTASIS [J].
AUGUST, DA ;
OTTOW, RT ;
SUGARBAKER, PH .
CANCER AND METASTASIS REVIEWS, 1984, 3 (04) :303-324
[2]   Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].
Bokemeyer, Carsten ;
Bondarenko, Igor ;
Makhson, Anatoly ;
Hartmann, Joerg T. ;
Aparicio, Jorge ;
de Braud, Filippo ;
Donea, Serban ;
Ludwig, Heinz ;
Schuch, Gunter ;
Stroh, Christopher ;
Loos, Anja H. ;
Zubel, Angela ;
Koralewski, Piotr .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[5]   Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study [J].
Douillard, Jean-Yves ;
Siena, Salvatore ;
Cassidy, James ;
Tabernero, Josep ;
Burkes, Ronald ;
Barugel, Mario ;
Humblet, Yves ;
Bodoky, Gyoergy ;
Cunningham, David ;
Jassem, Jacek ;
Rivera, Fernando ;
Kocakova, Ilona ;
Ruff, Paul ;
Blasinska-Morawiec, Maria ;
Smakal, Martin ;
Canon, Jean-Luc ;
Rother, Mark ;
Oliner, Kelly S. ;
Wolf, Michael ;
Gansert, Jennifer .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4697-4705
[6]  
Duffy MJ, 2001, CLIN CHEM, V47, P624
[7]   A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200 [J].
Giantonio, B. J. ;
Levy, D. E. ;
O'Dwyer, P. J. ;
Meropol, N. J. ;
Catalano, P. J. ;
Benson, A. B., III .
ANNALS OF ONCOLOGY, 2006, 17 (09) :1399-1403
[8]   Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis [J].
Golfinopoulos, Vassilis ;
Salanti, Georgia ;
Pavlidis, Nicholas ;
Ioannidis, John P. A. .
LANCET ONCOLOGY, 2007, 8 (10) :898-911
[9]   Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J].
Grothey, Axel ;
Van Cutsem, Eric ;
Sobrero, Alberto ;
Siena, Salvatore ;
Falcone, Alfredo ;
Ychou, Marc ;
Humblet, Yves ;
Bouche, Olivier ;
Mineur, Laurent ;
Barone, Carlo ;
Adenis, Antoine ;
Tabernero, Josep ;
Yoshino, Takayuki ;
Lenz, Heinz-Josef ;
Goldberg, Richard M. ;
Sargent, Daniel J. ;
Cihon, Frank ;
Cupit, Lisa ;
Wagner, Andrea ;
Laurent, Dirk .
LANCET, 2013, 381 (9863) :303-312
[10]   Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study [J].
Hochster, Howard S. ;
Hart, Lowell L. ;
Ramanathan, Ramesh K. ;
Childs, Barrett H. ;
Hainsworth, John D. ;
Cohn, Allen L. ;
Wong, Lucas ;
Fehrenbacher, Louis ;
Abubakr, Yousif ;
Saif, M. Wasif ;
Schwartzberg, Lee ;
Hedrick, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3523-3529